Summary:
- Alnylam Pharmaceuticals, a leading biopharmaceutical company, has announced that it will advance its investigational drug, zilebesiran, into a global Phase 3 cardiovascular outcomes trial.
- Zilebesiran is a potential treatment for cardiovascular disease, which is a major health concern worldwide. The drug works by targeting a specific gene that is involved in the regulation of cholesterol levels in the body.
- The Phase 3 trial will evaluate the safety and efficacy of zilebesiran in reducing the risk of major cardiovascular events, such as heart attacks and strokes, in patients with established cardiovascular disease or at high risk of developing it.